Wealth Enhancement Trust Services’s Compass Therapeutics CMPX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.62K	Buy	+740	New	+$2.19K	﹤0.01%	1032

Other funds holding CMPX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wealth Enhancement Trust Services's CMPX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 740 shares worth $1.62K. The stake represents ﹤0.01% of the portfolio and ranks #1032 among its holdings.

117 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

Wealth Enhancement Trust Services held 740 shares of Compass Therapeutics worth $1.62K as of Q2 2026.
Compass Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Compass Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1032 holding.
117 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.